Announcement of Tibet Weixinkang Pharmaceutical Co., Ltd. on application for comprehensive credit line in 2026 and related guarantee matters
Securities code: 603676 Securities abbreviation: Wei Xinkang Announcement number: 2026-006
Tibet Weixinkang Pharmaceutical Co., Ltd.
Announcement on Application for Comprehensive Credit Line and Related Guarantees in 2026
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Important content reminder:
Guaranteed objects and basic information
actually provide for it
balance of guarantee provided
Is this guarantee expected in the early stage? Does this guarantee have the name of the guaranteed person? The amount (excluding the principal)
Insured amount Counter-guarantee sub-guarantee within the limit
amount)
Tibet Weixinkang Pharmaceutical
Not applicable: This time only Not applicable: This time only joint stock companies and
1.5 billion yuan 0 yuan for 2026 for 2026 within the scope of consolidated statements
Estimated insurance coverage Subsidiaries with estimated insurance coverage
Cumulative guarantee status
Cumulative amount of overdue external guarantees (10,000 yuan) 0 Listed companies and their holdings as of the date of this announcement
150,000 (including the estimated guarantee for this time) Total external guarantees provided by subsidiaries (10,000 yuan)
The total amount of external guarantees accounted for the most recent period for listed companies.
101.60 Proportion of audited net assets (%)
The guarantee amount (including this time) exceeds the latest period of the listed company☑
50% of audited net assets
The total amount of external guarantees (including this time) exceeds that of listed companies recently☑
100% of the audited net assets of the first phase
Special risk warning (please check if applicable)
□The total amount of guarantees for units outside the consolidated statements (including this time) reaches or exceeds 30% of the latest audited net assets
□This time, guarantees will be provided to units with asset-liability ratios exceeding 70%.
protect
Other risk warnings (if any) None
1. Overview of guarantee situation
(1) Basic information on guarantee
In accordance with the provisions of the Company Law, Securities Law, Shanghai Stock Exchange Stock Listing Rules and other laws and regulations, as well as the Articles of Association and other rules and regulations, in order to meet the production and operation development needs of Tibet Weixinkang Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") in 2026, it is proposed to authorize the company and its subsidiaries to apply for a comprehensive credit and credit limit of 15 in 2026 from financial institutions including but not limited to the Lhasa Branch of Industrial and Commercial Bank of China Co., Ltd. Billion yuan, and the company and its subsidiaries will mutually guarantee the aforementioned credit and credit lines with their own credit or assets for a period of two years. At the same time, subject to the approval of the above-mentioned external guarantee line by the company's shareholders' meeting, the company's general manager or financial director will be further authorized to handle the above matters on behalf of the company (including but not limited to credit, borrowing, guarantees, mortgages, etc.). This authorization will be effective within one year from the date of review and approval by the shareholders' meeting. The final credit limit shall be subject to the actual credit limit approved by each bank. Within the authorization period, the credit limit can be used repeatedly.
(2) Internal decision-making procedures
The above guarantee matters have been reviewed and approved at the fifth meeting of the company's fourth board of directors and must be submitted to the 2025 annual shareholders' meeting for review and approval before implementation.
(3) Basic information on guarantee estimates
Guaranteed amount Yes
guaranteed
Guarantee as of this time No
The party's latest guarantee pre-payment is whether the guarantee is guaranteed by the guaranteed party. Currently, the newly added city company is related.
The first-phase capital calculation is valid. There is a countervailing party. The share ratio is guaranteed. Guarantee. The latest link
Assets and Liabilities Period Guarantee Example Balance Amount Net Assets Period Guarantee
rate
Proportion of production guaranteed
1. For holding subsidiaries
The asset-liability ratio of the secured party does not exceed 70%
from shareholders
Tibet Central Committee will review Yishi Company
Wei Chengkang Approval Jifa Jizi 100% 46.51% 0 200 million yuan 13.55% No
The pharmaceutical industry has a company that will last a lifetime from one day to the next.
Co., Ltd. will be valid within the year
from shareholders
Inner Mongolia
The meeting will review Yishi Corporation Baiyi System
Upon approval, Jifa and Ziyao shares 100% 8.27% 0 100 million yuan 6.77% No
From the date of birth, it is a company limited
There is a warrant company within the year
effective
2. For listed companies
The asset-liability ratio of the secured party does not exceed 70%
from shareholders
The meeting will review Yishi Company
Unsuitable 1.2 billion At the time of approval, Jifa and its subsidiaries 20.92% 0 81.28% No
Use Yuan to start a lifetime for the company
Accurate within the year
effective
(4) Adjustment of guarantee amount
Within the scope of the total guarantee limit, the guarantee limits between the company and its subsidiaries (including other subsidiaries not specified but within the scope of the company's consolidated statements, including newly established or acquired subsidiaries) can be adjusted mutually. This guarantee is not expected to include guarantees for companies with an asset-liability ratio of more than 70%.
2. Basic information of the guaranteed person
(1) Tibet Weixinkang Pharmaceutical Co., Ltd.
Type of guaranteed person Legal person
Name of the guaranteed party: Tibet Weixinkang Pharmaceutical Co., Ltd.
Type of guaranteed party and listed company
/
Company shareholding status
Tibet Wei Xinkang Enterprise Management Co., Ltd. directly holds 47.17% of the shares, Zhang Yong directly holds 12.27% of the shares, and Zhong Lijuan directly holds 8.27% of the shares. Major shareholders and shareholding ratios
Tianjin Jingwei Xinkang Management Consulting Partnership (Limited Partnership) directly holds 7.75% of the shares, and other shareholders hold a total of 24.54% of the shares.
Legal representative Liu Weiqiang
Unified social credit code 91540091785815591P
Established on March 17, 2006
Registration address: Building 4, Industrial Center, No. 5, Yuanyuan South Road, Zone B, Lhasa Economic and Technological Development Zone
3rd floor
Registered capital 435.1615 million yuan
Company type Other joint stock limited company (listed)
Medical technology research and development, technical consulting, technical services, and technology transfer; introduction and promotion of pharmaceutical technology; information consulting, investment consulting (excluding finance and business scope brokerage business); corporate management consulting, conference hosting, and display and exhibition services (excluding large-scale performances). [Projects that require approval according to law can only operate the activity after approval by the relevant departments]
December 31, 2025 December 31, 2024 Project
Main financial indicators (100 million yuan)/2025 (audited)/2024 (audited) total assets 18.67 18.54
Total liabilities 3.90 4.68
Net assets 14.76 13.85
Operating income 11.36 13.00
Net profit 2.33 2.46
(2) Tibet Zhongwei Chengkang Pharmaceutical Co., Ltd.
Type of guaranteed person Legal person
Name of guaranteed party Tibet Zhongwei Chengkang Pharmaceutical Co., Ltd.
Type of guaranteed party and listed company
Wholly owned subsidiary
Company shareholding status
Tibet Weixinkang Pharmaceutical Co., Ltd. holds 88.90% of the equity. Inner Mongolia’s main shareholder and shareholding ratio: Baiyi Pharmaceutical Co., Ltd. holds 11.10% of the equity.
(Note: The shareholding ratio is the ratio of shareholders’ actual capital contribution)
Legal representative Zeng Huan
Unified social credit code 9154009109577063X8
Established on March 25, 2014
Registration address: Building 4, Industrial Center, No. 5, Yuanyuan South Road, Zone B, Lhasa Economic and Technological Development Zone
3rd floor
Registered capital 175 million yuan
Company Type Other Limited Liability Company
Licensed projects: Wholesale of pharmaceuticals; sales of pharmaceutical excipients; commissioned pharmaceutical production (projects that require approval according to law can only be carried out after approval by relevant departments. Specific business projects are subject to the license documents of relevant departments)
General projects: business management consulting; marketing planning; market research (excluding foreign-related investigations); brand management; corporate image planning; project planning and business scope
Public relations services; technical services, technology development, technical consultation, technology exchange, technology transfer, technology promotion; information consulting services (excluding licensing information consulting services); information technology consulting services; medical research and experimental development (except for projects that require approval in accordance with the law, independently carry out business activities that are not prohibited or restricted by laws and regulations)
December 31, 2025 December 31, 2024 Project
/2025 (audited) /2024 (audited) total assets 5.93 7.16
Total liabilities 2.76 3.40
Main financial indicators (100 million yuan)
Net assets 3.17 3.76
Operating income 8.01 9.20
Net profit 1.01 1.24
(3) Inner Mongolia Baiyi Pharmaceutical Co., Ltd.
Type of guaranteed person Legal person
Name of guaranteed party Inner Mongolia Baiyi Pharmaceutical Co., Ltd.
Type of guaranteed party and listed company
Wholly owned subsidiary
Company shareholding status
Tibet Weixinkang Pharmaceutical Co., Ltd. holds 98.21% of the shares, Beijing Jing’s main shareholder and shareholding ratio
Wei Zhongzhi Pharmaceutical Technology Development Co., Ltd. holds 1.79% equity
Legal representative Feng Xuewen
Unified social credit code 91150000701336455A
Established on November 12, 2003
Place of registration: No. 5, Central Road, Ulanhot Economic and Technological Development Zone, Inner Mongolia Autonomous Region Registered capital: 140 million yuan
Company type Limited by shares (unlisted)
Produces freeze-dried powder injections and small-volume injections (201 workshop, 502 workshop); business scope produces large-volume injections, raw materials, hard capsules, granules, powders, tablets, and inhalation preparations. Road general cargo transportation
December 31, 2025 December 31, 2024 Project
/2025 (audited) /2024 (audited)
Total assets 4.55 3.75
Main financial indicators (100 million yuan) Total liabilities 0.38 0.22
Net assets 4.17 3.54
Operating income 1.78 1.20
Net profit 0.64 0.31
None of the above-mentioned guaranteed persons are persons subject to execution for breach of trust.
3. Main contents of the guarantee agreement
This guarantee is the estimated guarantee amount of the company and its subsidiaries in 2026. The agreement has not yet been signed. After review and approval by the company’s shareholders’ meeting, the main content of the specific guarantee agreement will be determined through consultation between the company and its subsidiaries and banks and other financial institutions.
4. Necessity and Reasonability of Guarantee
The above guarantee matters are to ensure the sustainable and steady development of the company's production and operation, and are estimated based on the current company's business situation, and meet the actual needs of the company's overall production and operation. The guarantee objects are all the company and its subsidiaries. The guarantee risks are generally controllable, and there is no behavior that damages the interests of the company and small and medium-sized shareholders.
5. Opinions of the Board of Directors
Since the above guarantees are all between the company and its subsidiaries or between subsidiaries, and the guarantee risks are controllable, the company's board of directors agrees with the above guarantee matters and agrees to submit them to the shareholders' meeting for review.
6. Cumulative number of external guarantees and number of overdue guarantees
As of the announcement date, except for this expected guarantee, the company and its subsidiaries have no actual external guarantees or overdue guarantees.
Announcement is hereby made.
Board of Directors of Tibet Weixinkang Pharmaceutical Co., Ltd.
April 24, 2026